21.25
1.59 (8.09%)
| Previous Close | 19.66 |
| Open | 19.81 |
| Volume | 355,690 |
| Avg. Volume (3M) | 582,770 |
| Market Cap | 397,720,960 |
| Price / Book | 1.50 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 0.87% |
| Current Ratio (MRQ) | 22.92 |
| Operating Cash Flow (TTM) | -62.89 M |
| Levered Free Cash Flow (TTM) | -69.56 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -41.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tectonic Therapeutic, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 38.29% |
| % Held by Institutions | 59.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 30 Sep 2025 | 302,953 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Dec 2025 | Announcement | Tectonic Therapeutic to Participate in December Investor Conferences |
| 06 Nov 2025 | Announcement | Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights |
| 29 Oct 2025 | Announcement | Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |